prod:prod_dcx-login
Xpert® vanA
The first rapid & accurate test to assist with VRE surveillance
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXVANA-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Collection Device (Pack of 50)
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
According to the Centers for Disease Control and Prevention (CDC), about 30% of all healthcare-associated enterococcal infections are caused by Vancomycin-Resistant Enterococci (VRE).1 However, VRE can be even more prevalent in high risk groups, such as immunocompromised and ICU patients.
The human and financial impact of VRE is high2:
The human and financial impact of VRE is high2:
- Attributable mortality: 10%
- Extended length of stay: 6.2 days
- Incremental cost: $12,800
* With EAT (Early Assay Termination), for Positive Results
(1)CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
(2)Carmeli Y, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002 Oct 28;162(19):2223-8.
(1)CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
(2)Carmeli Y, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002 Oct 28;162(19):2223-8.
The Solution
The CDC and SHEA have both published guidelines on how to reduce or eliminate healthcare associated infections.3,4 As a part of a quality infection control program, Cepheid's Xpert vanA provides:
- Rapid and accurate detection of the vanA gene most closely associated with VRE colonization
- Superior NPV required in a surveillance test
- Easy-to-use test with minimal hands-on time
(3)Siegel JD, et al. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007 Dec;35(10 Suppl 2):S165-93.
(4)Muto CA, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003 May;24(5):362-86.
(4)Muto CA, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003 May;24(5):362-86.
Related Products
Xpert Norovirus
Fast and accurate identification of Norovirus GI & GII in as little as one hour* *With early assay termination for positive results. Reporting negative results in 90 minutes.
Xpert MRSA/SA Blood Culture
Accurate Detection of MRSA and SA in Positive Blood Culture Specimens in About an Hour
Xpert MRSA NxG
Active MRSA surveillance testing in about an hour
Xpert C. difficile
Detection of Clostridium difficile in 40 minutes*
Xpert Carba-R
Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 48 minutes
Xpert MRSA/SA SSTI
Detect MRSA & SA Skin and Soft Tissue Infections In About One Hour
Xpert SA Nasal Complete
Pre-surgical S. aureus and MRSA in about an hour
Xpert C. difficile/Epi
45-minute detection & differentiation of Clostridium difficile & the Epidemic 027 strain